Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
| Autor: | Pivot, X., Verma, S., Fallowfield, L., Müller, V., Lichinitser, M., Jenkins, V., Sánchez Muñoz, A., Machackova, Z., Osborne, S., Gligorov, J. |
|---|---|
| Zdroj: | In European Journal of Cancer November 2017 86:82-90 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect